Home Tags Trastuzumab deruxtecan

Tag: Trastuzumab deruxtecan

Daiichi Sankyo and AstraZeneca Agree on Global Development and Commercialization for...

Daiichi Sankyo and AstraZeneca confirmed entering into a global development and commercialization agreement for datopotamab deruxtecan also know as DS-1062, a TROP2 directed DXd...

First Patients Dosed in Phase II Trial with Trastuzumab Duocarmazine in...

A first patient has started treatment in a Phase II study designed to evaluate the safety and efficacy of trastuzumab duocarmazine, also known...
Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

Trastuzumab deruxtecan Launced in Japan for Patients with HER2 Positive Unresectable...

This week Daiichi Sankyo announced the launch of trastuzumab deruxtecan (Enhertu®), a HER2 directed antibody-drug conjugate (ADC), in Japan.The newly approved agent is a...
Daiichi Sankyo

Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in...

In a statement earlier today, Daiichi Sankyo confirmed that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour...
Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

Netherlands Based Precision Medicines Developer Relaunches as Byondis

Netherlands-based Synthon Biopharmaceuticals, a biopharmaceutical research, and development company creating innovative precision medicines including the anti-HER2 investigational antibody-drug conjugate (ADC) trastuzumab duocarmazine, previously known...

Advancements in the Development of ADC-technology for Cancer Treatment

In an article published in Future Drug Discovery, Justyna Mysliwy, Bioconjugation Team Leader at Iksuda Therapeutics, writes about the de developments in the technology...
Daiichi Sankyo, Basking Ridge, NJ. Courtesy: Daiichi Sankyo.

DESTINY-Gastric01 Trial of Trastuzumab Deruxtecan Versus Chemotherapy Met Primary Endpoint

The pivotal phase II DESTINY-Gastric01 trial (NCT03329690) of known as trastuzumab deruxtecan, previously known as DS-8201, in patients with HER2+ unresectable or metastatic gastric...

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-positive Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca)*, a HER2 directed antibody-drug conjugate or ADC, for...
Speakers and attendees during the morning sessions on Wednesday December 11, 2019. during the San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center in San Antonio, TX. This year is the 42nd Anniversary of the meeting where over 7,500 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Photo Courtesy 2019 © MedMeetingImages/Todd Buchanan

SABCS 2019: DESTINY-Breast01 Trial of Trastuzumab Deruxtecan Shows Positive Results in...

Detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial (NCT03248492) of trastuzumab deruxtecan (DS-8201; fam-trastuzumab deruxtecan in the US only) were presented...
Gesso Italiano (Italian Chalk) in San Diego's Little Italy neighborhood celebrating its heritage by bringing the vibrancy and flavors of Italy to southern California. Courtesy: 2016 Fotolia.

Advanced Design of ADCs: Principles and Applications using Next Generation Linkers...

Over the years there have been major challenges in the development of antibody-drug conjugates (ADC), including: choosing the right target, right antibody, right linker,...